Targets of new biotech Alzheimer Parkinson and ALS

December 16, 2014 1:32 AM

4 0

Targets of new biotech Alzheimer Parkinson and ALS

There are over 50 million people suffering for neurodegenerative diseases and people realised the treatment needs for this diseases.A new company Yumanity announced to focuse on this diseases with their new biotech team.This team includes top experts on diseases which became popular like ice bucket challenge as we remember.This team will force with many diseases on many conditions. Yumanity signifies a partnership between Susan Lindquist, a 2009 winner of the National Medal of Science and member of the Whitehead Institute at the Massachusetts Institute of Technology, and Tony Coles, who was most recently the chairman and CEO of the San Francisco-based cancer drug maker Onyx Pharmaceuticals, which was acquired by Amgen in late 2013 for $10.5 billion. Coles will relocate to Boston to assume the role of chairman and chief executive officer of the company.

There are over 50 million people suffering for neurodegenerative diseases and people realised the treatment needs for this diseases.A new company Yumanity announced to focuse on this diseases with their new biotech team.This team includes top experts on diseases which became popular like ice bucket ...

Read more

To category page

Loading...